Clovis Oncology (CLVS) Stock Price, News & Analysis

Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.08 to $1.09
• 52-Week Range: N/A
• Volume: 1.16 million shs
• Average Volume: 8.88 million shs
• Market Capitalization: $11.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Clovis Oncology Stock Analysis - MarketRank™

Clovis Oncology scored higher than 8% of companies evaluated by MarketBeat, and ranked 939th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Clovis Oncology.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Clovis Oncology are expected to grow in the coming year, from ($1.68) to ($0.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clovis Oncology is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CLVS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clovis Oncology does not currently pay a dividend.

Dividend Growth

Clovis Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.33

Short Interest

There is no current short interest data available for CLVS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CLVS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Clovis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Clovis Oncology is held by insiders.

Percentage Held by Institutions

Only 24.53% of the stock of Clovis Oncology is held by institutions.

CLVS Stock Analysis - Frequently Asked Questions

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to analyst estimates of $38.73 million.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

• Last Earnings: 11/03/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLVS
• CUSIP: 18946410
• CIK: 1466301
• Web: www.clovisoncology.com
• Phone: 303-625-5000
• Fax: 303-245-0360
• Employees: N/A
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-264,520,000.00
• Net Margins: -189.37%
• Pretax Margin: -189.68%
• Return on Equity: N/A
• Return on Assets: -57.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $148.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.15) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 144,955,000
• Free Float: 138,577,000
• Market Cap: $11.60 million
• Optionable: Optionable
• Beta: 0.24